NCT06126861已完成1 期
The Mass Balance Study of [14C]LP-168 in Chinese Healthy Subjects
Guangzhou Lupeng Pharmaceutical Company LTD.1 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2023年12月25日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Radioactivity concentration of blood and plasma sample
研究概览
简要总结
This study is a single-center, open-label, single-dose clinical pharmacokinetic study. The purpose of this study is to investigate the absorption characteristics, as well as to evaluate the metabolism and elimination pathways after a single oral dose of 150mg, 100μCi [14C]LP-168 in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male subjects
- •Aged 18-45 (including the boundary value);
- •Body weight over 50 kg, the body mass index (BMI) is between 19 and 26 kg/m2 (including the boundary value);
- •Subjects must sign the informed consent form voluntarily;
- •Agree to abide the requirements of the study protocol, willing to communicate with the study doctor.
排除标准
- •After a comprehensive physical examination, vital signs, laboratory tests and other examinations are abnormal and have clinical significance;
- •Hepatitis B surface antigen or E antigen, hepatitis C virus antibody IgG (Anti-HCV IgG), human immunodeficiency virus antigen/antibody combined test (HIV-Ag/Ab) and Treponema pallidum antibody test positive;
- •Subject with clinically significant abnormalities on ophthalmologic examination (slit lamp, intraocular pressure and fundus photography)
- •Subject who have used any drug that inhibits or induces hepatic drug metabolizing enzymes or transporters during the screening period and within the previous 28 days;
- •Subject who have taken any medication with inhibition gastric acid secretion during the screening period and within the previous 28 days
- •Subject who have taken any anti-gastric acid medication during the screening period and within the previous 28 days
- •Subject who have used any systemic medication during the screening period and within the previous 14 days
- •Subject with a history of any clinically serious illness or disease or condition that, in the opinion of the investigator, may affect the results of the trial
- •Subject with any condition that may affect the absorption of the drug
- •Subject with history of organic heart disease, heart failure, myocardial infarction, angina pectoris, unexplained arrhythmia, ventricular tachycardia, atrioventricular block, QT prolongation syndrome, or symptoms of QT prolongation syndrome or family history of these syndrome.
- •Subject with major surgery during the screening period and within the previous 6 months or surgical incisions that have not fully healed
- •Subject with allergies, such as a known history of allergy to two or more substances
- •Subject with hemorrhoids or perianal disease with regular or ongoing blood in the stool, irritable bowel syndrome, inflammatory bowel disease
- •Subject with habitual constipation or diarrhea
- •Subject with alcohol abuse or regular use of alcohol in the 6 months prior to the screening period
- •Subject with smoking >5 cigarettes per day before the first 3 months of the screening period
- •Subject with drug abuse
- •Subject who are subjected to long-term exposure to radioactive conditions
- •Subject who have difficulty collecting blood or cannot tolerate venipuncture for blood collection
- •Subject with participation in any other clinical trial during the screening period and within the previous 3 months
- •Subject who have been vaccinated during the screening period and within the previous 1 month or who are scheduled to be vaccinated during the trial period
- •Subject with plans to have children or donate sperm during the trial and within 1 year after completion of the trial
- •Subject who had lost or donated up to 400 mL of blood during the screening period and within the previous 3 months, or those who had received a blood transfusion within 1 month;
- •Subject with any factors that the investigator believes make participation in this trial inappropriate
研究组 & 干预措施
[14C]LP-168
Experimental
Using 14C-labeled LP-168 as a marker to investigate the absorption characteristic, as well as to evaluate the metabolism and elimination pathways in healthy subjects
干预措施: [14C]LP-168 (Drug)
结局指标
主要结局
Radioactivity concentration of blood and plasma sample
时间窗: Day 1- Day 8
Use liquid scintillation counter to evaluate Radioactivity concentration of each sample
Radioactivity concentration of urine and feces sample
时间窗: Day 1- Day 15
Use liquid scintillation counter to evaluate Radioactivity concentration of each sample
Number of metabolites and its proportion in plasma, urine and feces.
时间窗: Day 1- Day 15
To study the metabolite profiling
次要结局
- Plasma LP-168/Major Metabolic concentrations(Day 1- Day 8)
- Treatment emergent adverse events as assessed by CTCAE 5.0(Day 1- Day 15)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
The Mass Balance Study of [14C]JT001Healthy SubjectsNCT05802810Shanghai Vinnerna Biosciences Co., Ltd.7
已完成
1 期
Study to Evaluate the Mass Babance and Biotransformation of [14C]SHR6390 in Healthy Adult Male VolunteersHealthy Adult Male VolunteersNCT04616742Jiangsu HengRui Medicine Co., Ltd.6
已完成
1 期
Study Evaluating Oral Administrations of HKI-272 in Healthy Male SubjectsHealthyNCT00550212Puma Biotechnology, Inc.6
已完成
1 期
Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR4640 in Chinese Healthy Adult Male Volunteers.Healthy Adult Male VolunteersNCT04260373Jiangsu HengRui Medicine Co., Ltd.6
已完成
1 期
Mass Balance Study of [14C]HLX208 in China Healthy SubjectsMass Balance Study in Healthy SubjectsNCT05841940Shanghai Henlius Biotech6